These results highlight the capabilities of Cytonus’ innovative Cargocyte™ platform in addressing solid tumor penetration challenges. Importantly, Cargocytes offer localized delivery of potent immunotherapies in a controlled manner to enhance their safety profile.
“While immunocytokine therapeutics can modulate the immune system, systemic delivery often results in adverse events and toxicity which limits their clinical utility. What is remarkable about our data is that we demonstrate a historically toxic cytokine (IL-12) can be localized to metastatic sites with exquisite accuracy and without systemic off-target effects. Our unique approach leads to a substantial reduction in metastatic burden and as such has potential to treat patients with late-stage cancers,” said Dr. Remo Moomiaie-Qajar, M.D. co-founder and CEO of Cytonus Therapeutics.
Also Read: Kinetic Deploying High-Speed Fiber Internet to Connect Nearly 4,250 Pulaski County Locations
“Arguably the most exciting discovery in immune oncology in the past decade has been the development of immune checkpoint inhibitors (ICI). Unfortunately, only 13% of all patients respond to ICI therapy. Our data clearly demonstrates the ability of CA-IL-12 to make recalcitrant tumors (TNBC) responsive to ICI therapy. These promising findings demonstrates the enabling nature of CA-IL-12 to expand the utility of ICI to the large number of cancer patients normally refractory to this approach,” said Dr. Moomiaie-Qajar, M.D.
About Cargocyte™
Cargocyte products are derived from enucleated cell lines and are uniquely engineered with specific disease targeting molecules to safely transport therapeutic payloads intravenously and deep into difficult-to-reach target tissues. Cargocytes can deliver and actively produce the therapeutic agent of choice on-site in a controlled,
About Cytonus Therapeutics
Cytonus Therapeutics Inc. is a San Diego-based biotech company developing proprietary therapeutic products to treat unmet needs in cancer, CNS, and inflammatory diseases.